Predictive factors of neoadjuvant immune checkpoint blockade in melanoma

References

• Robert C, Ribas A, Schachter J, Arance A, Grob -J-J, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–9. doi:https://doi.org/10.1016/S1470-2045(19)30388-2.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391–98. doi:https://doi.org/10.1200/JCO.2017.72.2850.
   PubMed Web of Science ®Google Scholar
• Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J Clin Med. 2020;9. doi:https://doi.org/10.3390/jcm9010223.
   Google Scholar
• Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835–44. doi:https://doi.org/10.1016/S0140-6736(20)30934-X.
   PubMed Web of Science ®Google Scholar
• Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018;67(12):1833–44. doi:https://doi.org/10.1007/s00262-018-2241-x.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandalà M, Del Vecchio M, Gogas H, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez Rodas I, et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: updated results from a phase III trial (CheckMate 238). J Clin Oncol. 2018;36(suppl; abstr 9502). doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.9502.
   Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. doi:https://doi.org/10.1056/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. doi:https://doi.org/10.1056/NEJMoa1802357.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:2105–2110.
   Web of Science ®Google Scholar
• Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma. J Surg Oncol. 2020 Mar;123(3):782–788.
   Web of Science ®Google Scholar
• Robert C. Is earlier better for melanoma checkpoint blockade? Nat Med. 2018;24:1645–48. doi:https://doi.org/10.1038/s41591-018-0250-0.
   PubMed Web of Science ®Google Scholar
• Kretschmer L, Thoms KM, Peeters S, Haenssle H, Bertsch H-P, Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res. 2008;18:16–21. doi:https://doi.org/10.1097/CMR.0b013e3282f2017d.
   PubMed Web of Science ®Google Scholar
• Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN, et al. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010;17(10):2764–72. doi:https://doi.org/10.1245/s10434-010-1026-z.
   PubMed Web of Science ®Google Scholar
• Faut M, Heidema RM, Hoekstra HJ, Van Ginkel RJ, Been SLB, Kruijff S, van Leeuwen BL. Morbidity after inguinal lymph node dissections: it is time for a change. Ann Surg Oncol. 2017;24(2):330–39. doi:https://doi.org/10.1245/s10434-016-5461-3.
   PubMed Web of Science ®Google Scholar
• Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. 2020;27:15–21. doi:https://doi.org/10.1245/s10434-019-07830-w.
   PubMed Web of Science ®Google Scholar
• Puza CJ, Bressler ES, Terando AM, Howard JH, Brown MC, Hanks B, Salama AKS, Beasley GM. The emerging role of surgery for patients with advanced melanoma treated with immunotherapy. J Surg Res. 2019;236:209–15. doi:https://doi.org/10.1016/j.jss.2018.11.045.
   PubMed Web of Science ®Google Scholar
• Rauwerdink DJW, Molina G, Frederick DT, Sharova T, van der Hage J, Cohen S, Boland GM. Mixed response to immunotherapy in patients with metastatic melanoma. Ann Surg Oncol. 2020;27(9):3488–97. doi:https://doi.org/10.1245/s10434-020-08657-6.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE), Cancer Therapy Evaluation Program (CTEP). National cancer institute (NIH) division of cancer treatment & diagnosis (DCTD). 2020.
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:https://doi.org/10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8(1):e000398. doi:https://doi.org/10.1136/jitc-2019-000398.
   PubMed Web of Science ®Google Scholar
• Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29(8):1861–68. doi:https://doi.org/10.1093/annonc/mdy226.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Eggermont AMM. Neoadjuvant therapy in melanoma: the next step? Lancet Oncol. 2018;19:151–53. doi:https://doi.org/10.1016/S1470-2045(18)30016-0.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68. doi:https://doi.org/10.1016/S1470-2045(16)30366-7.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:https://doi.org/10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob -J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. doi:https://doi.org/10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. doi:https://doi.org/10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, et al. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018;6(1):112. doi:https://doi.org/10.1186/s40425-018-0428-5.
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–61. doi:https://doi.org/10.1038/s41591-019-0357-y.
   PubMed Web of Science ®Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–61. doi:https://doi.org/10.1038/s41591-018-0198-0.
   PubMed Web of Science ®Google Scholar
• Versluis JM, Rozeman EA, Menzies A, Reijers I, Krijgsman O, Hoefsmit EP, van de Wiel BA, Sikorska K, Bierman C, Dimitriadis P, et al. L3 update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients. J Immunother Cancer. 2020;8:A2.1–A2. doi:https://doi.org/10.1136/jitc-2020-ITOC7.3.
   Google Scholar
• Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–60. doi:https://doi.org/10.1016/S1470-2045(19)30151-2.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu W-J, Hanna E, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54. doi:https://doi.org/10.1038/s41591-018-0197-1.
   PubMed Web of Science ®Google Scholar
• Lebbe C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019 Apr;10;37(11):867–875.
   Web of Science ®Google Scholar
• Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2018:CD012974.
   Google Scholar
• Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362. doi:https://doi.org/10.1126/science.aar3593.
   Google Scholar
• Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8 + T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. Cancer Immunol Res. 2018;6(1):14–24. doi:https://doi.org/10.1158/2326-6066.CIR-17-0249.
   PubMed Web of Science ®Google Scholar
• Crampton SP, Deane JA, Feigenbaum L, Bolland S. Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J Immunol. 2012;188(3):1451–59. doi:https://doi.org/10.4049/jimmunol.1102705.
   PubMed Web of Science ®Google Scholar
• Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711–723.e4. doi:https://doi.org/10.1016/j.ccell.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102–09. doi:https://doi.org/10.1200/JCO.2016.67.2477.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria J-C, Rugo HS, Cohen RB, O’Neil BH, Mehnert JM, et al. T-Cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318–27. doi:https://doi.org/10.1200/JCO.2018.78.2276.
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi:https://doi.org/10.1038/nature22079.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. doi:https://doi.org/10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–65. doi:https://doi.org/10.1038/s41586-019-1914-8.
   PubMed Web of Science ®Google Scholar
• Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell’Aquila E, Anesi C, Silvestris N, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39(1):95. doi:https://doi.org/10.1186/s13046-020-01601-2.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol. 2016;13:487–503. doi:https://doi.org/10.1038/nrclinonc.2016.1.
   PubMed Web of Science ®Google Scholar
• Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JFR. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol. 2009;35:113–22. doi:https://doi.org/10.1016/j.ejso.2008.03.015.
   PubMed Web of Science ®Google Scholar
• Sabanathan D, Eslick GD, Shannon J. Use of neoadjuvant chemotherapy plus molecular targeted therapy in colorectal liver metastases: a systematic review and meta-analysis. Clin Colorectal Cancer. 2016;15:e141–e147. doi:https://doi.org/10.1016/j.clcc.2016.03.007.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu W-J, Tawbi HA, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19(2):181–93. doi:https://doi.org/10.1016/S1470-2045(18)30015-9.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Rozeman EA, Amaria RN, Huang AC, Scolyer RA, Tetzlaff MT, Van De Wiel BA, Lo S, Tarhini AA, Tawbi HA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC). Nat Med. 2019;37:9503–9503.
   Google Scholar
• Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, ten Haken B, Muller SH, Bierman C, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br J Surg. 2019;106(5):519–22. doi:https://doi.org/10.1002/bjs.11168.
   PubMed Web of Science ®Google Scholar
• Blank CU, Reijers ILM, Pennington T, Versluis JM, Saw RP, Rozeman EA, Kapiteijn E, Van Der Veldt AA, Suijkerbuijk K, Hospers G, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. 2020;38:10002–10002.
   Google Scholar
• Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium. Lancet Oncol. 2019;20(7):e378–e389. doi:https://doi.org/10.1016/S1470-2045(19)30332-8.
   PubMed Web of Science ®Google Scholar